Hedge fund Quadrature Capital Ltd significantly increased its stake in Vertex Pharmaceuticals Incorporated during the third quarter of 2025, boosting its total holdings by over 700% to 149,908 shares. This substantial investment suggests strong confidence from Quadrature Capital in Vertex’s pipeline and future growth prospects as a leading biotech company developing treatments for serious diseases like cystic fibrosis. The move signals increased investor confidence in Vertex’s continued success in innovative treatment development.
Quadrature Capital Ltd Boosts Vertex Pharmaceuticals Stake
Hedge fund Quadrature Capital Ltd significantly increased its stake in Vertex Pharmaceuticals Incorporated during the third quarter of 2025, boosting its total holdings by over 700% to 149,908 shares. This substantial investment suggests strong confidence from Quadrature Capital in Vertex’s pipeline and future growth prospects as a leading biotech company developing treatments for serious diseases like cystic fibrosis. The move signals increased investor confidence in Vertex’s continued success in innovative treatment development.